App-Quantinova.ai

Are adolescents prepared for transition? A survey of practice in Northern Ireland

Claire Masih - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

What impact does JIA have on health-related quality of life over time and by gender?

Andrew Smith - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cryopyrin associated periodic syndrome

N/A

Young Ambassadors Project: engaging patients attending a specialised young adult clinic

Ines Soares - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Factors associated with change in health-related quality of life in people living with gout: a three-year prospective cohort study in primary care

Lorraine Watson - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

N/A

The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome: 24-month follow-up of an open-label, parallel group, randomised controlled trial

Claire L Burton - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Familial carpal tunnel syndrome

Methylprednisolone Acetate

Validation of the Musculoskeletal Health Questionnaire (MSK-HQ) in patients with musculoskeletal pain in primary care

Ian C Scott - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preterm premature rupture of the membranes

N/A

A review of vitamin D testing in primary care: significant savings to be made

Emily Riding - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ergocalciferol

Undertaking an integrated nurse led review (INCLUDE) for patients with inflammatory conditions: does it change management of morbidities?

Samantha Hider - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Osteoporosis

N/A

Gastrointestinal symptoms and proton pump inhibitor use in patients with polymyalgia rheumatica: results from the PMR Cohort study

Hamzeh Feddah - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Haematopoietic stem cell transplantation in systemic sclerosis: Sheffield Teaching Hospitals’ experience

Ruth Smith - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Influence of patient reported arthritis activity in determining sHAQ, HAQ-DI and Cochin scores in systemic sclerosis

Klodian Gjeloshi - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Forced vital capacity in patients with systemic sclerosis associated pulmonary fibrosis: predictors of meaningful decline

Svetlana I Nihtyanova - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary fibrosis

N/A

Skin score trajectory associates with survival and pulmonary outcome in diffuse cutaneous systemic sclerosis

Svetlana I Nihtyanova - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Tocilizumab in systemic sclerosis: real world experience from a single centre cohort supports potential benefit on lung function for anti-topoisomerase (Scl-70) positive subgroup

Kristina E. N Clark - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Tocilizumab

Stage and subset specific profiles of fibrogenesis highlighted through analysis of serum markers across the scleroderma spectrum

Kristina E. N Clark - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Co-existence of scleroderma hallmark autoantibodies associates with distinct clinical phenotype

Corrado Campochiaro - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Rituximab

Understanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach

Fiza Ahmed - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Altered iron homeostasis and pulmonary haemodynamics in systemic sclerosis associated pulmonary arterial hypertension

Alper Sari - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Severity of hand vascular involvement as assessed by MRI Digital Artery Volume Index (DAVIX©) predicts worsening of clinical parameters and patient reported outcomes in scleroderma

Fiammetta Danzo - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Current patient reported outcomes (PROs) poorly reflect changes in lung function in patients with systemic sclerosis

Fiammetta Danzo - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Raynaud syndrome

N/A

Filters

45280 Abstracts